MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 8, 2008; DOI: 10.1124/mol.107.042697


0026-895X/08/7304-1168-1184$20.00
Mol Pharmacol 73:1168-1184, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.042697v1
73/4/1168    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Park, M. A.
Right arrow Articles by Dent, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, M. A.
Right arrow Articles by Dent, P.

OSU-03012 Stimulates PKR-Like Endoplasmic Reticulum-Dependent Increases in 70-kDa Heat Shock Protein Expression, Attenuating Its Lethal Actions in Transformed Cells

Margaret A. Park, Adly Yacoub, Mohammed Rahmani, Guo Zhang, Lori Hart, Michael P. Hagan, Stuart K. Calderwood, Michael Y. Sherman, Costas Koumenis, Sarah Spiegel, Ching-Shih Chen, Martin Graf, David T. Curiel, Paul B. Fisher, Steven Grant, and Paul Dent

Departments of Biochemistry (M.A.P., A.Y., M.R., G.Z., S.S., S.G., P.D.), Medicine (M.R., S.G.), Neurosurgery (M.G.), and Radiation Oncology (A.Y.), Virginia Commonwealth University, Richmond, Virginia; Division of Medicinal Chemistry, College of Pharmacy, the Ohio State University, Columbus, Ohio (C.-S.C.); Departments of Radiation Oncology (C.K.) and Hematology/Oncology (L.H.), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Department of Radiation Oncology, Harvard University, Boston, Massachusetts (S.K.C.); Departments of Pathology, Neurosurgery and Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York (P.B.F.); Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama (D.T.C.); and Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts (M.Y.S.)

We have further defined mechanism(s) by which 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}acetamide [OSU-03012 (OSU)], a derivative of the cyclooxygenase-2 (COX2) inhibitor celecoxib but lacking COX2 inhibitory activity, kills transformed cells. In cells lacking expression of protein kinase R-like endoplasmic reticulum kinase (PERK-/-), the lethality of OSU was attenuated. OSU enhanced the expression of Beclin 1 and ATG5 and cleavage of pro-caspase 4 in a PERK-dependent fashion and promoted the Beclin 1- and ATG5-dependent formation of vacuoles containing LC3, followed by a subsequent caspase 4-dependent cleavage of cathepsin B and a cathepsin B-dependent formation of low pH intracellular vesicles; cathepsin B was activated and released into the cytosol and genetic suppression of caspase 4, cathepsin B, or apoptosis-inducing factor function significantly suppressed cell killing. In parallel, OSU caused PERK-dependent increases in 70-kDa heat shock protein (HSP70) expression and decreases in 90-kDa heat shock protein (HSP90) and Grp78/BiP expression. Changes in HSP70 expression were post-transcriptional. Knock-down or small-molecule inhibition of HSP70 expression enhanced OSU toxicity, and overexpression of HSP70 suppressed OSU-induced low pH vesicle formation and lethality. Our data demonstrate that OSU-03012 causes cell killing that is dependent on PERK-induced activation of multiple toxic proteases. OSU-03012 also increased expression of HSP70 in a PERK-dependent fashion, providing support for the contention that OSU-03012-induced PERK signaling promotes both cell survival and cell death processes.


Received October 15, 2007; accepted December 20, 2007

Address correspondence to: Dr. Paul Dent, Department of Biochemistry, 401 College Street, Massey Cancer Center, Room 280a, Box 980035, Virginia Commonwealth University, Richmond, VA 23298-0035. E-mail: pdent{at}vcu.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics